Xenon Pharmaceuticals(XENE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

XENE Xenon Pharmaceuticals

Post-Mkt 12-11 16:28:42 EST

43.66

+0.22

+0.51%

盘后43.66

+0.000.00%

16:10 EST

High44.54	Low42.89	Vol856.35K
Open43.44	D1 Closing43.44	Amplitude3.81%
Mkt Cap3.37B	Tradable Cap3.13B	Total Shares77.28M
T/O37.53M	T/O Rate1.20%	Tradable Shares71.60M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"XENE","market":"US","secType":"STK","nameCN":"Xenon Pharmaceuticals","latestPrice":43.66,"timestamp":1765486800000,"preClose":43.44,"halted":0,"volume":856352,"hourTrading":{"tag":"盘后","latestPrice":43.66,"preClose":43.66,"latestTime":"16:10 EST","volume":24883,"amount":1086442.168075,"timestamp":1765487404415},"delay":0,"floatShares":71595579,"shares":77275005,"eps":-3.886555,"marketStatus":"Post-Mkt","change":0.22,"latestTime":"12-11 16:28:42 EST","open":43.44,"high":44.54,"low":42.8864,"amount":37533896.746,"amplitude":0.038066,"askPrice":44.51,"askSize":44,"bidPrice":42.82,"bidSize":46,"shortable":3,"etf":0,"ttmEps":-3.886555,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1765501200000},"marketStatusCode":4,"adr":0,"adrRate":0,"listingDate":1415163600000,"exchange":"NASDAQ","adjPreClose":43.44,"preHourTrading":{"tag":"盘前","latestPrice":43.25,"preClose":43.44,"latestTime":"09:05 EST","volume":1455,"amount":63232.949759999996,"timestamp":1765461945126},"postHourTrading":{"tag":"盘后","latestPrice":43.66,"preClose":43.66,"latestTime":"16:10 EST","volume":24883,"amount":1086442.168075,"timestamp":1765487404415},"volumeRatio":1.286978,"impliedVol":0.9487,"impliedVolPercentile":0.944},"requestUrl":"/m/hq/s/XENE/tweets","defaultTab":"tweets","newsList":[{"id":"2590548065","title":"Xenon Pharmaceuticals Is Maintained at Overweight by Wells Fargo","url":"https://stock-news.laohu8.com/highlight/detail?id=2590548065","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590548065?lang=en_us&edition=fundamental","pubTime":"2025-12-12 01:22","pubTimestamp":1765473720,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/XENE/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 11, 2025 12:22 ET (17:22 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XENE"],"gpt_icon":0},{"id":"2590373298","title":"Xenon Pharmaceuticals CEO Ian Mortimer Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2590373298","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590373298?lang=en_us&edition=fundamental","pubTime":"2025-12-10 08:40","pubTimestamp":1765327247,"startTime":"0","endTime":"0","summary":"Ian Mortimer, President & CEO of Xenon Pharmaceuticals Inc., reported a disposal of common shares of Xenon Pharmaceuticals Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xenon Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 09, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251210:nNDLbHcTgN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Xenon Pharmaceuticals CEO Ian Mortimer Reports Disposal of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","XENE"],"gpt_icon":0},{"id":"2589818552","title":"Xenon Pharmaceuticals Reports 48-Month Azetukalner Study Shows 90.9% Seizure Reduction in Epilepsy Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2589818552","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589818552?lang=en_us&edition=fundamental","pubTime":"2025-12-05 22:00","pubTimestamp":1764943230,"startTime":"0","endTime":"0","summary":"Xenon Pharmaceuticals Inc. has announced new data from its ongoing clinical development in epilepsy, including interim 48-month results from the X-TOLE open-label extension  study of azetukalner in patients with focal onset seizures. According to the company, participants treated for 48 months or longer experienced a monthly reduction in seizure frequency of 90.9%, with 38% achieving at least one year of seizure freedom. The new data suggest that long-term use of azetukalner may enable patients to attain and regain extended periods of seizure freedom, including in those with difficult-to-treat disease. These results, along with multiple real-world studies on the burden of depression and anti-seizure medication titration in epilepsy, are being presented at the American Epilepsy Society Annual Meeting , held from December 5-9, 2025, in Atlanta, Georgia. Additionally, new pre-clinical research in Dravet syndrome was presented, indicating potential for improved motor function through Na V ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251205:nNDL9LsGqD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","LU2210150020.SGD","IE00B64PRP62.GBP","LU0314104364.USD","NDAQ","IE00B3QW5Z07.USD","IE00BKPKM429.USD","BK4588","IE00BGHQF748.EUR","BK4585","XENE","BK4112","BK4139","LU2095319765.USD"],"gpt_icon":0},{"id":"2589934858","title":"Xenon Pharmaceuticals Grants Equity Inducements to New Employees","url":"https://stock-news.laohu8.com/highlight/detail?id=2589934858","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589934858?lang=en_us&edition=fundamental","pubTime":"2025-12-05 06:20","pubTimestamp":1764886807,"startTime":"0","endTime":"0","summary":"Xenon Pharmaceuticals Inc. has granted equity inducement awards to five new non-officer employees, totaling 39,250 share options. The options have an exercise price of $44.61 per common share, reflecting the closing price on December 4, 2025. The options vest over four years, with 25% vesting on the first anniversary of each employee's start date, and the remaining shares vesting in equal monthly installments over the following three years. Each option has a 10-year term.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xenon Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire  on December 04, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nNDL96MByH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","LU2210150020.SGD","IE00B64PRP62.GBP","LU0314104364.USD","NDAQ","IE00B3QW5Z07.USD","IE00BKPKM429.USD","BK4588","IE00BGHQF748.EUR","BK4585","XENE","BK4112","BK4139","LU2095319765.USD"],"gpt_icon":0},{"id":"2589385892","title":"Press Release: Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2589385892","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589385892?lang=en_us&edition=fundamental","pubTime":"2025-12-05 06:20","pubTimestamp":1764886800,"startTime":"0","endTime":"0","summary":"VANCOUVER, British Columbia and BOSTON, Dec. 04, 2025  -- Xenon Pharmaceuticals Inc. , a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced equity inducement grants to five new non-officer employees consisting of an aggregate of 39,250 share options. All of the foregoing share options were approved by the Compensation Committee of the Company's Board of Directors with an effective date of December 4, 2025 and were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635.Xenon and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in the US, Canada, and elsewhere. All other trademarks belong to their respective owner.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2271345857.HKD","BK4581","LU1804176565.USD","LU2746668461.USD","IE00BZ1G4Q59.USD","LU2746668974.SGD","LU1633808545.USD","LU1712237335.SGD","LU0265550946.USD","LU1623119135.USD","LU1917777945.USD","LU1934455863.HKD","LU0417517546.SGD","BK4139","LU0289960550.SGD","LU0950375773.USD","LU1974910355.USD","LU1852331112.SGD","XENE","LU2361044865.SGD","SG9999017495.SGD","BK4534","LU0642271901.SGD","LU0868494617.USD","LU1046421795.USD","LU1363072403.SGD","LU0353189680.USD","LU1035775433.USD","LU0345774391.USD","LU0971096721.USD","LU0472753341.HKD","LU2242649171.HKD","V","SG9999014880.SGD","LU1803068979.SGD","LU0057025933.USD","LU0158827781.USD","LU0251132253.USD","LU0823417737.USD","LU2360032135.SGD","IE00BQXX3D17.EUR","LU2361044949.HKD","LU0079474960.USD","LU0476273544.USD","IE00BQXX3C00.GBP","LU0348723411.USD","SG9999014914.USD","NQmain","LU1228905037.USD","BK4533"],"gpt_icon":0},{"id":"2588769700","title":"Xenon Pharmaceuticals CEO Ian Mortimer Reports Sale of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2588769700","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588769700?lang=en_us&edition=fundamental","pubTime":"2025-12-04 09:21","pubTimestamp":1764811274,"startTime":"0","endTime":"0","summary":"Ian Mortimer, President & CEO of Xenon Pharmaceuticals Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xenon Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 03, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nNDL46wRny:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Xenon Pharmaceuticals CEO Ian Mortimer Reports Sale of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XENE","BK4139"],"gpt_icon":0},{"id":"2588418350","title":"Xenon Pharmaceuticals to Present Azetukalner and Epilepsy Data at AES 2025 Webinar","url":"https://stock-news.laohu8.com/highlight/detail?id=2588418350","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588418350?lang=en_us&edition=fundamental","pubTime":"2025-12-03 21:30","pubTimestamp":1764768620,"startTime":"0","endTime":"0","summary":"Xenon Pharmaceuticals Inc. will host a webinar titled \"Azetukalner and Epilepsy Data Update: AES 2025\" on Wednesday, December 10, 2025, from 10:00 to 11:00 AM Eastern Time. The event will include an update on the company's progress in preparing for the commercialization of azetukalner, and questions can be submitted in advance or during the live session. A live webcast will be available on the Investors section of Xenon's website and will be posted for replay following the event.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xenon Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire  on December 03, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nNDL8XV4by:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","IE00B64PRP62.GBP","LU0314104364.USD","XENE","LU2210150020.SGD","NDAQ","IE00BKPKM429.USD","IE00B3QW5Z07.USD","LU2095319765.USD","IE00BGHQF748.EUR","BK4139","BK4585","BK4112","BK4588"],"gpt_icon":0},{"id":"2586791052","title":"Xenon Pharmaceuticals (XENE): Evaluating Valuation as New Epilepsy and Dravet Data Draw Investor Attention","url":"https://stock-news.laohu8.com/highlight/detail?id=2586791052","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586791052?lang=en_us&edition=fundamental","pubTime":"2025-11-28 07:30","pubTimestamp":1764286233,"startTime":"0","endTime":"0","summary":"Xenon Pharmaceuticals (XENE) is preparing to present a series of research updates at the American Epilepsy Society Annual Meeting. The company will feature new long-term data on its key drug candidates for epilepsy and Dravet syndrome.\nSee our latest analysis for Xenon Pharmaceuticals.\nAfter gaining attention with its AES meeting announcement, Xenon Pharmaceuticals has seen its momentum build, posting a 15.3% 90-day share price return and an impressive 3-year total shareholder return of...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-xene/xenon-pharmaceuticals/news/xenon-pharmaceuticals-xene-evaluating-valuation-as-new-epile","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-xene/xenon-pharmaceuticals/news/xenon-pharmaceuticals-xene-evaluating-valuation-as-new-epile","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["XENE"],"gpt_icon":0},{"id":"2586251593","title":"Wells Fargo Sticks to Its Buy Rating for Xenon (XENE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2586251593","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586251593?lang=en_us&edition=fundamental","pubTime":"2025-11-26 19:57","pubTimestamp":1764158261,"startTime":"0","endTime":"0","summary":"In a report released today, Benjamin Burnett from Wells Fargo maintained a Buy rating on Xenon, with a price target of $44.00. Burnett covers the H...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/wells-fargo-sticks-to-its-buy-rating-for-xenon-xene-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/wells-fargo-sticks-to-its-buy-rating-for-xenon-xene-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XENE"],"gpt_icon":0},{"id":"2586491475","title":"Xenon Pharmaceuticals Unveils New Long-Term Azetukalner Data in Epilepsy at AES 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2586491475","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586491475?lang=en_us&edition=fundamental","pubTime":"2025-11-25 21:30","pubTimestamp":1764077421,"startTime":"0","endTime":"0","summary":"Xenon Pharmaceuticals Inc. announced that it will present new clinical data at the upcoming American Epilepsy Society Annual Meeting , scheduled for December 5-9, 2025, in Atlanta, Georgia. The company will share seven posters, including new long-term data from the ongoing X-TOLE open-label extension study of azetukalner in patients with focal onset seizures. Additional presentations will cover patterns of seizure freedom with extended azetukalner use, the impact of depression on epilepsy patients, and pre-clinical data from Xenon's NaV1.1 program in Dravet syndrome. The results are set to be presented at the conference and will be available after the live sessions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xenon Pharmaceuticals I","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251125:nNDL5gPlkk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU2210150020.SGD","IE00B64PRP62.GBP","XENE","IE00B3QW5Z07.USD","BK4588","NDAQ","IE00BKPKM429.USD","BK4585","LU2210149790.SGD","BK4112","LU2095319765.USD","IE00BGHQF748.EUR","LU0314104364.USD"],"gpt_icon":0},{"id":"2584925310","title":"Xenon Pharmaceuticals Q3 Net Income USD -90.896 Million Vs. IBES Estimate USD -91.3 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2584925310","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584925310?lang=en_us&edition=fundamental","pubTime":"2025-11-20 00:27","pubTimestamp":1763569639,"startTime":"0","endTime":"0","summary":"Nov 03 (Reuters) - Xenon Pharmaceuticals Q3 operating expenses USD 96.336 million.:  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))  Source Date/Time = 03-NOV-202520:38:07.723 GMT","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nRSD4XjtqK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XENE","BK4139"],"gpt_icon":0},{"id":"2584995181","title":"Xenon Pharmaceuticals Is Maintained at Overweight by JP Morgan","url":"https://stock-news.laohu8.com/highlight/detail?id=2584995181","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584995181?lang=en_us&edition=fundamental","pubTime":"2025-11-18 23:56","pubTimestamp":1763481360,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/XENE/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 18, 2025 10:56 ET (15:56 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XENE"],"gpt_icon":0},{"id":"2584324709","title":"Xenon Pharmaceuticals price target raised to $60 from $57 at JPMorgan","url":"https://stock-news.laohu8.com/highlight/detail?id=2584324709","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584324709?lang=en_us&edition=fundamental","pubTime":"2025-11-18 20:36","pubTimestamp":1763469412,"startTime":"0","endTime":"0","summary":"JPMorgan raised the firm’s price target on Xenon Pharmaceuticals (XENE) to $60 from $57 and keeps an Overweight rating on the shares. The firm upda...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/xenon-pharmaceuticals-price-target-raised-to-60-from-57-at-jpmorgan-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/xenon-pharmaceuticals-price-target-raised-to-60-from-57-at-jpmorgan-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XENE"],"gpt_icon":0},{"id":"2584598847","title":"Xenon Pharmaceuticals Inc : JP Morgan Raises Target Price to $60 From $57","url":"https://stock-news.laohu8.com/highlight/detail?id=2584598847","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584598847?lang=en_us&edition=fundamental","pubTime":"2025-11-18 13:17","pubTimestamp":1763443044,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251118:nFWN3WT1UF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","XENE"],"gpt_icon":0},{"id":"2583680025","title":"H.C. Wainwright Sticks to Their Buy Rating for Xenon (XENE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2583680025","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583680025?lang=en_us&edition=fundamental","pubTime":"2025-11-15 07:38","pubTimestamp":1763163516,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Douglas Tsao maintained a Buy rating on Xenon today and set a price target of $53.00. According to TipRanks, Tsao is a 5-st...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-sticks-to-their-buy-rating-for-xenon-xene-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-sticks-to-their-buy-rating-for-xenon-xene-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XENE"],"gpt_icon":0},{"id":"2582368848","title":"Xenon Pharmaceuticals (XENE): Fresh Valuation Perspective Following Modest Share Price Uptick","url":"https://stock-news.laohu8.com/highlight/detail?id=2582368848","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582368848?lang=en_us&edition=fundamental","pubTime":"2025-11-11 18:20","pubTimestamp":1762856429,"startTime":"0","endTime":"0","summary":"Xenon Pharmaceuticals (XENE) saw its stock edge up slightly at the last close, gaining about 0.4%. Investors have been watching the company’s long-term performance, with shares rising 7% over the past 3 months.\nSee our latest analysis for Xenon Pharmaceuticals.\nXenon Pharmaceuticals’ share price return over the past year is still down double digits, but its 5-year total shareholder return of more than 250% signals the bigger story here has been about long-term momentum building behind the...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-xene/xenon-pharmaceuticals/news/xenon-pharmaceuticals-xene-fresh-valuation-perspective-follo","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-xene/xenon-pharmaceuticals/news/xenon-pharmaceuticals-xene-fresh-valuation-perspective-follo","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["XENE","BK4139","DCF"],"gpt_icon":0},{"id":"2582817349","title":"H.C. Wainwright Reaffirms Their Buy Rating on Xenon (XENE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2582817349","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582817349?lang=en_us&edition=fundamental","pubTime":"2025-11-10 09:15","pubTimestamp":1762737349,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Douglas Tsao maintained a Buy rating on Xenon yesterday and set a price target of $53.00. Tsao covers the Healthcare sector...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-reaffirms-their-buy-rating-on-xenon-xene-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-reaffirms-their-buy-rating-on-xenon-xene-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XENE"],"gpt_icon":0},{"id":"2581091979","title":"Xenon Pharmaceuticals to Present at Key Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2581091979","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581091979?lang=en_us&edition=fundamental","pubTime":"2025-11-06 22:15","pubTimestamp":1762438505,"startTime":"0","endTime":"0","summary":"An update from Xenon ( ($XENE) ) is now available. Xenon Pharmaceuticals announced its participation in two upcoming investor conferences, the Stif...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/xenon-pharmaceuticals-to-present-at-key-investor-conferences?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/xenon-pharmaceuticals-to-present-at-key-investor-conferences?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","XENE"],"gpt_icon":0},{"id":"2581725098","title":"Xenon Pharmaceuticals (XENE): Revenue Forecasts Soar 72.4% as Profitability Concerns Persist","url":"https://stock-news.laohu8.com/highlight/detail?id=2581725098","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581725098?lang=en_us&edition=fundamental","pubTime":"2025-11-05 15:48","pubTimestamp":1762328912,"startTime":"0","endTime":"0","summary":"Xenon Pharmaceuticals (XENE) reported continued unprofitability in its latest quarter and is projected to remain in the red for at least three more years. Over the past five years, losses have grown at an average yearly rate of 37%. However, revenue growth is forecast to accelerate at 72.4% per year, outpacing both the broader US market and the biotech sector. Despite substantial top-line momentum, margins and net profit have yet to improve, keeping earnings quality under pressure.\nSee our...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-xene/xenon-pharmaceuticals/news/xenon-pharmaceuticals-xene-revenue-forecasts-soar-724-as-pro","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-xene/xenon-pharmaceuticals/news/xenon-pharmaceuticals-xene-revenue-forecasts-soar-724-as-pro","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["XENE"],"gpt_icon":0},{"id":"2581712018","title":"Xenon (XENE) Receives a Buy from Evercore ISI","url":"https://stock-news.laohu8.com/highlight/detail?id=2581712018","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581712018?lang=en_us&edition=fundamental","pubTime":"2025-11-05 14:16","pubTimestamp":1762323382,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Cory Kasimov from Evercore ISI maintained a Buy rating on Xenon, with a price target of $55.00. The company’s share...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/xenon-xene-receives-a-buy-from-evercore-isi-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/xenon-xene-receives-a-buy-from-evercore-isi-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","XENE"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.xenon-pharma.com","stockEarnings":[{"period":"1week","weight":-0.0192},{"period":"1month","weight":0.131},{"period":"3month","weight":0.1671},{"period":"6month","weight":0.326},{"period":"1year","weight":0.0372},{"period":"ytd","weight":0.1082}],"compareEarnings":[{"period":"1week","weight":0.0054},{"period":"1month","weight":0.009},{"period":"3month","weight":0.0455},{"period":"6month","weight":0.1517},{"period":"1year","weight":0.1406},{"period":"ytd","weight":0.1732}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, a Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epileptic encephalopathy; and XEN1101, a Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy. The company was incorporated in 1996 and is headquartered in Burnaby, Canada.","yearOnYearQuotes":[{"month":1,"riseRate":0.454545,"avgChangeRate":0.016807},{"month":2,"riseRate":0.727273,"avgChangeRate":0.078057},{"month":3,"riseRate":0.181818,"avgChangeRate":-0.075368},{"month":4,"riseRate":0.545455,"avgChangeRate":0.022894},{"month":5,"riseRate":0.363636,"avgChangeRate":-0.037416},{"month":6,"riseRate":0.454545,"avgChangeRate":0.032291},{"month":7,"riseRate":0.363636,"avgChangeRate":0.01913},{"month":8,"riseRate":0.727273,"avgChangeRate":0.07504},{"month":9,"riseRate":0.181818,"avgChangeRate":-0.05886},{"month":10,"riseRate":0.454545,"avgChangeRate":0.054946},{"month":11,"riseRate":0.727273,"avgChangeRate":0.050412},{"month":12,"riseRate":0.583333,"avgChangeRate":0.087173}],"exchange":"NASDAQ","name":"Xenon Pharmaceuticals","nameEN":"Xenon Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Xenon Pharmaceuticals(XENE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Xenon Pharmaceuticals(XENE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Xenon Pharmaceuticals,XENE,Xenon Pharmaceuticals股票,Xenon Pharmaceuticals股票老虎,Xenon Pharmaceuticals股票老虎国际,Xenon Pharmaceuticals行情,Xenon Pharmaceuticals股票行情,Xenon Pharmaceuticals股价,Xenon Pharmaceuticals股市,Xenon Pharmaceuticals股票价格,Xenon Pharmaceuticals股票交易,Xenon Pharmaceuticals股票购买,Xenon Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Xenon Pharmaceuticals(XENE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Xenon Pharmaceuticals(XENE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}